183 related articles for article (PubMed ID: 8622115)
1. Overview of the efficacy of isepamicin in the adult core clinical trial programme.
Carbon C
J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
Beaucaire G
J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
Covi M; Velluti G
J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Colardyn F
J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
[TBL] [Abstract][Full Text] [Related]
6. An overview of the safety of isepamicin in adults.
Blum D
J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
[TBL] [Abstract][Full Text] [Related]
7. Once daily isepamicin treatment in complicated urinary tract infections.
Lee SS; Liu YC; Wann SR; Lin WR; Tsai TH; Lin HH; Chen YS; Yen MY
J Microbiol Immunol Infect; 1999 Jun; 32(2):105-10. PubMed ID: 11561574
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
Petrikkos G; Giamarellou H; Tsagaraki C; Pefanis A
J Chemother; 1995 Jun; 7 Suppl 2():161-4. PubMed ID: 8622106
[TBL] [Abstract][Full Text] [Related]
9. Isepamicin versus amikacin in the treatment of urinary tract infection.
Sturm W
J Chemother; 1995 Jun; 7 Suppl 2():149-54. PubMed ID: 8622104
[TBL] [Abstract][Full Text] [Related]
10. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
[TBL] [Abstract][Full Text] [Related]
11. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients.
Viganò A; Principi N
J Chemother; 1995 Jun; 7 Suppl 2():95-101. PubMed ID: 8622117
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections.
Leal del Rosal P
J Chemother; 1995 Jun; 7 Suppl 2():143-8. PubMed ID: 8622103
[TBL] [Abstract][Full Text] [Related]
13. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
[TBL] [Abstract][Full Text] [Related]
18. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
Sweileh WM
Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
[TBL] [Abstract][Full Text] [Related]
19. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
20. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
